This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.


This independent activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Multiple Myeloma View Time: 22 mins

touchEXPERT BRIEFING The evolving treatment landscape in relapsed/refractory multiple myeloma

Watch leading experts Shaji Kumar and Rahma Warsame discuss the current and evolving treatment landscape in relapsed/refractory multiple myeloma, as well as key factors influencing treatment decisions.

Now Playing:
Up Next:
Expert Interviews
The current treatment landscape for relapsed/refractory multiple myeloma – what are the choices?

Shaji Kumar and Rahma Warsame discuss the key factors influencing treatment decisions in relapsed/refractory multiple myeloma, using a variety of patient scenarios.

view bio and disclosures
1/2 Next Interview
Evolution of relapsed/refractory multiple myeloma therapy – where are we headed?

Rahma Warsame and Shaji Kumar discuss the current landscape in relapsed/refractory multiple myeloma, and how treatment paradigms may evolve in the future.

view bio and disclosures
2/2 Leave Feedback
Leave Feedback
Overview & Learning Objectives

In recent years, the treatment landscape for multiple myeloma has evolved rapidly1. This has led to a complicated overall picture for treatment sequencing in the relapsed/refractory setting, involving a variety of patient-, tumour- and treatment-related factors1.

In addition, treatment becomes more challenging after each relapse, as multiple therapies enrich for resistant malignant clones and the cumulative toxicity of therapies increases, while bone marrow function decreases2. As such, achieving optimal treatment sequencing is key to preventing or delaying recurrent relapses following first-line therapy and improving patient prognosis2.

Learning Objectives

After watching this activity, participants should be better able to:

  • Provide an overview of the treatment landscape for relapsed/refractory multiple myeloma (r/r MM).
  • Describe key factors that influence treatment decisions and treatment sequencing in r/r MM.
  • Discuss how new and developing treatments may impact the r/r MM treatment landscape and decision-making.
Faculty & Disclosures
Dr Shaji K Kumar

Division of Hematology, Mayo Clinic, Minnesota

The research of Shaji Kumar, M.D., focuses on development of novel drugs for treatment of myeloma. Dr Kumar’s research team evaluates the in vitro activity of novel drugs that, based on their mechanisms of action, are likely to have activity in the setting of myeloma. Promising drugs are brought into the clinic through early-stage clinical trials in Phase I or II studies.

Dr Kumar also evaluates novel combinations of different drugs to identify synergistic combinations that can result in better treatment responses and eventually better patient outcomes. His work on drug development is complemented by an active program studying the biology of myeloma, with a focus on the study of bone marrow microenvironment in multiple myeloma and how it influences the tumor cells, especially the increased bone marrow microvessels seen in myeloma. His clinical research focuses on outcomes of patients with myeloma and amyloidosis, especially high-risk disease.

Dr Shaji Kumar discloses: Research funding for clinical trials to the institution from: Abbvie, Amgen, BMS, Carsgen, Janssen, Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio and Molecular Templates; Consulting/Advisory Board participation (with no personal payments) from: Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secura Biotherapeutics, Monterosa therapeutics, Trillium and (with personal payment) Oncopeptides, Beigene, Antengene and GLH Pharma.

Dr Rahma Warsame

Division of Hematology, Mayo Clinic, Minnesota

The research of Rahma Warsame, M.D., is focused on amyloidosis and multiple myeloma. Dr Warsame is interested in investigating existing health care delivery systems to improve patient-reported outcomes and quality of life. She is also working on incorporating patient perspectives into clinical practice and determining its effect on clinical outcomes.

Dr Rahma Warsame discloses: No known competing financial interests or personal relationships that could have appeared to influence the content of this activity.

  1. 1. van de Donk NWCJ. Sequencing multiple myeloma therapies with and after antibody therapies. Hematology Am Soc Hematol Educ Program 2020;2020:248–258.
  2. 2. Nikitorowicz-Buniak J. Sequencing treatments for relapsed/refractory multiple myeloma. Multiple Myeloma Hub 2022; available at (accessed 22 December 2022).
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 9 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Feedback Close

Please provide feedback for this touchEXPERT BRIEFING on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

* = Mandatory Field

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72